Want to see ORGS full AI Analyst Report?
ORGS Stock Chart & Stats
$0.16
$0.04(1.86%)
At close: 4:00 PM EST
$0.16
$0.04(1.86%)
Day’s Range― - ―
52-Week Range<$0.01 - $1.58
Previous CloseN/A
Volume307.00
Average Volume (3M)979.00
Market Cap
$3.92M
Enterprise Value$23.43M
Total Cash (Recent Filing)$204.00K
Total Debt (Recent Filing)$17.30M
Price to Earnings (P/E)―
Beta13.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,799,538
10 Day Avg. Volume591
30 Day Avg. Volume979
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-6.91
Price to Sales (P/S)273.66
P/FCF Ratio-8.57
Enterprise Value/Market Cap5.98
Enterprise Value/Revenue-1.82
Enterprise Value/Gross Profit-1.28
Enterprise Value/Ebitda-0.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business Model InnovationThe POCare platform represents a strategic shift towards decentralized therapy production, potentially reducing costs and improving patient access, which can enhance long-term market positioning and competitiveness.
Strategic PartnershipsStrategic partnerships and licensing agreements expand Orgenesis' market reach and revenue potential, fostering sustainable growth and innovation in the biotech sector.
Corporate GovernanceEnhancements in corporate governance through board expansion may lead to better strategic oversight and operational improvements, supporting long-term organizational stability and growth.
Bears Say
Financial InstabilityNegative equity and financial instability indicate a leveraged position, posing risks to financial health and necessitating urgent strategic realignment or external support.
Liquidity IssuesNegative cash flows highlight liquidity constraints, limiting the company's ability to fund operations and invest in growth, potentially affecting long-term viability.
Revenue DeclineDeclining revenue and negative profit margins suggest operational inefficiencies, threatening growth prospects and necessitating strategic interventions to reverse trends.
Orgenesis News
ORGS FAQ
What was Orgenesis Inc’s price range in the past 12 months?
Orgenesis Inc lowest stock price was <$0.01 and its highest was $1.58 in the past 12 months.
What is Orgenesis Inc’s market cap?
Orgenesis Inc’s market cap is $3.92M.
When is Orgenesis Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Orgenesis Inc’s earnings last quarter?
Currently, no data Available
Is Orgenesis Inc overvalued?
According to Wall Street analysts Orgenesis Inc’s price is currently Overvalued.
Does Orgenesis Inc pay dividends?
Orgenesis Inc does not currently pay dividends.
What is Orgenesis Inc’s EPS estimate?
Orgenesis Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orgenesis Inc have?
Orgenesis Inc has 9,799,538 shares outstanding.
What happened to Orgenesis Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Orgenesis Inc?
Currently, no hedge funds are holding shares in ORGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orgenesis Inc
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.